ERBB2 and breast cancer: Kaplan–Meier survival curve analysis revealed no significant differences in overall survival (OS) between HER2‐low and HER2‐0 groups across the entire cohort (log‐rank p = 0.091), as well as in HR‐positive breast cancer and TNBC subgroups (p = 0.843 and 0.167, respectively) (Figure 1a–c).